Trial
NCT04552899
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
PRM-151 (Zinpentraxin Alfa)
Why stopped
The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-18